Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.054 AUD | +10.20% | +5.88% | -60.00% |
Apr. 02 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
Apr. 02 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
Valuation
Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 34.1 | 22.24 | 15.89 | - | - |
Enterprise Value (EV) 1 | 34.1 | 22.24 | 17.99 | 17.89 | -5.815 |
P/E ratio | -2.79 x | -1.05 x | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | 1.46 x | 0.9 x | 0.3 x |
EV / Revenue | - | - | 1.65 x | 1.02 x | -0.11 x |
EV / EBITDA | - | - | -2.34 x | -6.62 x | -0.24 x |
EV / FCF | - | - | -1.5 x | -5.26 x | -0.25 x |
FCF Yield | - | - | -66.7% | -19% | -408% |
Price to Book | - | - | - | - | 0.49 x |
Nbr of stocks (in thousands) | 110,004 | 143,466 | 294,175 | - | - |
Reference price 2 | 0.3100 | 0.1550 | 0.0490 | 0.0490 | 0.0490 |
Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | 10.9 | 17.6 | 52.2 |
EBITDA 1 | - | - | -7.7 | -2.7 | 24.6 |
EBIT 1 | - | - | -8 | -2.9 | 24.3 |
Operating Margin | - | - | -73.39% | -16.48% | 46.55% |
Earnings before Tax (EBT) 1 | - | - | -8.3 | -3.4 | 23.9 |
Net income 1 | -11.38 | -19.06 | -8.3 | -3.4 | 23.9 |
Net margin | - | - | -76.15% | -19.32% | 45.79% |
EPS 2 | -0.1110 | -0.1470 | - | - | - |
Free Cash Flow 1 | - | - | -12 | -3.4 | 23.7 |
FCF margin | - | - | -110.09% | -19.32% | 45.4% |
FCF Conversion (EBITDA) | - | - | - | - | 96.34% |
FCF Conversion (Net income) | - | - | - | - | 99.16% |
Dividend per Share | - | - | - | - | - |
Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | 2.1 | 2 | - |
Net Cash position 1 | - | - | - | - | 21.7 |
Leverage (Debt/EBITDA) | - | - | -0.2727 x | -0.7407 x | - |
Free Cash Flow 1 | - | - | -12 | -3.4 | 23.7 |
ROE (net income / shareholders' equity) | - | - | - | - | 96.4% |
ROA (Net income/ Total Assets) | - | - | - | - | 56.4% |
Assets 1 | - | - | - | - | 42.38 |
Book Value Per Share 2 | - | - | - | - | 0.1000 |
Cash Flow per Share 2 | - | - | -0.0400 | -0.0100 | 0.0800 |
Capex 1 | - | - | 0.3 | 0.3 | 0.3 |
Capex / Sales | - | - | 2.75% | 1.7% | 0.57% |
Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-60.00% | 9.54M | |
+12.87% | 227B | |
+12.77% | 192B | |
+15.97% | 136B | |
+28.27% | 108B | |
+1.29% | 64.07B | |
+17.22% | 52.1B | |
+6.74% | 51.87B | |
+9.86% | 44.33B | |
+4.00% | 36.75B |
- Stock Market
- Equities
- CDX Stock
- Financials CardieX Limited